Future work will further probe the mechanism of epithelial lineage plasticity induced by TFE3-fusions and continue to refine the conditions in which mTOR kinase inhibition may have therapeutic efficacy in human fusion-driven tRCC and PEComas. This evidence concerns the gene TFE3 and neoplasm with perivascular epithelioid cell differentiation.